Latest News

ZOTA

Zota Health Care to transfer unclaimed dividends and shares from FY 2017-18 to IEPF by Sep 16, 2025

Source |13:05 14 Jun 25

corporate actions regulatory filings

Zota Health Care Limited announced the compulsory transfer of unclaimed/unpaid dividends and corresponding shares for the financial year 2017-18 to the Investor Education and Protection Fund (IEPF).
This transfer is mandated by Section 124(5) and 124(6) of the Companies Act, 2013, read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as the dividend/shares have remained unclaimed/unpaid for seven consecutive years.
The transfer to the IEPF Authority is scheduled for September 16, 2025.
Shareholders whose dividend for the financial year 2017-18 remains unclaimed/unpaid are advised to claim it before September 15, 2025, to avoid the transfer.
To claim, shareholders must submit necessary documents, including Forms ISR-1, ISR-2, ISR-3 or SH-13, a duly filled Dividend claim form along with a self-attested copy of PAN card, original cancelled cheque, address proof, and original dividend warrants or a duly filled indemnity bond, to Satellite Corporate Services Pvt Ltd (the Company's Share Registrar & Transfer Agent) or the Company's registered office.
For shares held in DEMAT form, a copy of the Client Master List (CML) showing name, address, Demat and Bank account details, along with original dividend warrants or a duly filled indemnity bond, should be sent via email.
After the transfer, no claim shall lie against the Company. However, shareholders can claim the amount and shares from IEPF by submitting an online application in the prescribed Form IEPF-5 available on www.iepf.gov.in.

ZOTA

Zota Health Care acquires additional equity shares in Davaindia Health Mart for ₹49.24 crore

Source |12:15 13 Jun 25

mergers & acquisitions corporate actions

Zota Health Care Limited (ZOTA) announced on June 13, 2025, the acquisition of 1,18,518 equity shares of its Wholly Owned Subsidiary (WOS), Davaindia Health Mart Limited (DIHML), through a rights issue.

The acquisition was made for a cash consideration of ₹49,24,42,290/-, at a cost of ₹4155 per equity share (including a premium of ₹4145 per share).
This investment is considered a strategic move to support DIHML's working capital requirements.
Post-acquisition, DIHML continues to remain a WOS of Zota Health Care Limited.
DIHML, incorporated on January 01, 2020, operates a retail Generic Pharmacy chain under the Company Owned Company Operated (COCO) model of Davaindia Generic Pharmacy.
It has a presence in 15+ states and 1 Union Territory, with approximately 900+ stores offering over 2000 SKUs including medicines, ayurvedic products, cosmetics, nutraceuticals, and OTC products.
Financial details for DIHML:
- Turnover for Financial Year 2024-25: ₹109.93 crores
- Turnover for Financial Year 2023-24: ₹44.77 crores
- Turnover for Financial Year 2022-23: ₹14.61 crores
- Total paid-up share capital as of FY 2024-25: ₹2.13 crores
The acquisition does not fall under related party transactions.

ZOTA

Zota Health Care to meet with Kotak Securities Limited on June 18, 2025.

Source |14:11 12 Jun 25

corporate actions agm-egm

Zota Health Care Limited will participate in a meeting with Kotak Securities Limited on June 18, 2025, via virtual mode.
The meeting will involve a one-on-one discussion, utilizing the Business Update Presentation that includes financial results up to March 2025.
The presentation is already in the public domain and available on the company's and stock exchange websites.
No unpublished price-sensitive information will be shared during the meeting.

ZOTA

Zota Health Care Allots 3.03 Lakh Equity Shares on Warrant Conversion

Source |13:08 10 Jun 25

corporate actions fundraising

Zota Health Care Limited has allotted 3,03,065 fully paid-up equity shares of ₹10 each, at an issue price of ₹509 each (including a premium of ₹499).
This allotment was approved by the Board of Directors on June 10, 2025, upon the conversion of 3,03,065 fully convertible warrants.
The company received ₹11,56,95,063.75 (Rupees Eleven Crore Fifty Six Lakh Ninety Five Thousand Sixty Three and Seventy Five Paisa) from three non-promoter warrant holders as the warrant exercise money (75% of the issue price).
Consequent to this allotment, the company's paid-up equity capital has increased from ₹29,46,35,170 (2,94,63,517 equity shares) to ₹29,76,65,820 (2,97,66,582 equity shares).
The newly allotted equity shares rank pari passu with the existing equity shares.
Following this conversion, 18,33,375 warrants remain outstanding.

ZOTA

Zota Health Care Ltd Announces Q4FY25/FY25 Results and Expansion Plans

Source |13:58 04 Jun 25

results corporate actions strategic partnerships

Zota Health Care Limited announced the transcript of the Q4FY25/FY25 earnings conference call held on May 30, 2025.
The company's mission is to make healthcare affordable for all, focusing on manufacturing, marketing, and exporting pharmaceutical, ayurvedic, nutraceutical, and OTC products.
Zota operates through four key verticals:
Retail pharmacy chain - Davaindia
Domestic marketing business
Export business
Everyday Herbal Group
Davaindia has grown to 1,637 active stores as of May 16, 2025, offering generic medicines at 30% to 90% lower prices than branded counterparts.
901 COCO stores are operational as of May 16, with an online B2C platform for doorstep delivery.
736 FOFO stores are also in operation.
Domestic Marketing Business distributes branded medicines, OTC, and pharmaceutical products through 1,050 distributors nationwide, with a portfolio of around 4,000 products.
Export business has a presence in over 30 countries, with 325 product approvals out of 586 dossiers submitted.
In 2024, Zota acquired a 56% stake in Everyday Herbal Group to strengthen its OTC and cosmetic product portfolio.
Consolidated revenue from operations grew by 62% year-on-year, reaching ₹292.98 crore from ₹180 crore in FY24. Davaindia contributed ₹186 crore, growing 80% year-on-year.
Domestic sales stood at ₹63 crore, growing 11% year-on-year, while export business grew at 59%, reaching ₹32 crore.
Everyday Herbal Group contributed ₹11 crore to the revenue.
Gross profit increased by 86% year-on-year, reaching ₹155 crore compared to ₹84 crore in FY24.
Zota expanded its Davaindia network to 1,582 stores as of March 31, 2025, including 852 COCO stores and 730 FOFO stores, adding 702 new stores during FY25.
Customer footfall increased from 51.8 lakh to 97.7 lakh, and GMV rose sharply to ₹245 crore from ₹137 crore.
The company plans to add more than 1.6 COCO stores per day in FY26, with potential for faster expansion.
The company closed 18-19 COCO stores in the last quarter due to relocation and inventory-related losses.
EBITDA may remain flat for the current financial year due to aggressive expansion, with plans to open approximately 800 to 900 more COCO stores.
The company plans to expand into insulin and other diabetes-related therapies, actively tracking off-patent opportunities.
The company is willing to explore better efficiencies in supply chain.
Himanshu Zota (Founder and Whole Time Director) mentioned that for 36 month old stores the average GMV per store is around ₹6.4 lakhs per month, and store-level EBITDA is approximately ₹1.5 lakhs per month per store.